progressive dysphagia
Conditions
Interventions
ctDNA-positive group:None
ctDNA-negative group:None
Sponsors
Beijing Chao-Yang Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Histologically confirmed resectable locally advanced ESCC, stage T2N+M0 or T3-4aN0/+M0; 2. Aged >=18 years; 3. Received neoadjuvant therapy (paclitaxel + platinum + PD-1 inhibitor, 2-3 cycles) and achieved R0 resection; 4. Can tolerate adjuvant therapy post-surgery (2-3 cycles chemo-immunotherapy + maintenance immunotherapy up to 1 year); 5. Adequate tissue and peripheral blood samples available for testing; 6. ECOG performance status 0-1; 7. Adequate major organ function; 8. Signed informed consent and ability to comply with the study protocol; 9. Expected post-surgery survival >= 6 months.
Exclusion criteria
Exclusion criteria: 1. History of other concurrent or prior malignancies; 2. Lack of detailed histopathological report; 3. History of allogeneic organ or stem cell transplantation, or blood transfusion within 6 months before enrollment; 4. Unable to provide post-surgical landmark (1-6 weeks post-op, before adjuvant therapy) samples or technical failure of sample testing; 5. Pregnant or lactating women; 6. Other conditions deemed unsuitable by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 2-year disease-free survival rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival (OS);Disease-free survival (DFS);Lead time of ctDNA monitoring;Sensitivity of ctDNA assay;Specificity of ctDNA assay; | — |
Countries
China
Contacts
Public ContactMiao Jinbai
Beijing Chao-Yang Hospital, Capital Medical University
Outcome results
None listed